Mechanism of intrinsic resistance of lung squamous cell carcinoma to epithelial growth factor receptor‑tyrosine kinase inhibitors revealed by high‑throughput RNA interference screening

Ju,Lixia; Dong,Zhiyi; Yang,Juan; Li,Minghua

doi:10.3892/ol.2020.12218

Mechanism of intrinsic resistance of lung squamous cell carcinoma to epithelial growth factor receptor‑tyrosine kinase inhibitors revealed by high‑throughput RNA interference screening

Authors:
- Lixia Ju
- Zhiyi Dong
- Juan Yang
- Minghua Li
View Affiliations

Affiliations: Department of Integrative Medicine, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University, Shanghai 200433, P.R. China, Department of Emergency, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University, Shanghai 200433, P.R. China, Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shang University of Traditional Chinese Medicine, Shanghai 200071, P.R. China
Published online on: October 15, 2020 https://doi.org/10.3892/ol.2020.12218
Article Number: 363
Copyright: © Ju et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although targeted therapy has achieved a great breakthrough in the treatment of lung adenocarcinoma, there are still no effective targeted drugs for lung squamous cell carcinoma (SqCC). In addition, as immunotherapy can only prolong the overall survival (OS) of lung SqCC by ≤5 months, chemotherapy and radiotherapy are still the main types of therapy for advanced SqCC. The expression level of epithelial growth factor receptor (EGFR) in patients with lung SqCC is higher compared with those with adenocarcinoma, but the former group is intrinsically resistant to EGFR‑tyrosine kinase inhibitors (EGFR‑TKIs). Therefore, if the drug resistance in patients with lung SqCC could be reversed, the majority of patients may benefit from EGFR‑TKIs. In the present study, the high‑throughput RNA interference technology was used to screen the genes involved in the EGFR‑TKI erlotinib resistance of lung SqCCs, and integrin‑linked kinase (ILK) was identified to be the most effective. The role of ILK in erlotinib resistance was further studied in cell lines, and the expression of ILK was analyzed in patients with SqCC and adenocarcinoma. Finally, the mechanism of ILK in EGFR‑TKIs resistance was analyzed using Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO) and ingenuity pathway analysis (IPA). The results demonstrated that the ILK gene knockdown could overcome erlotinib resistance by inhibiting cell proliferation, inducing apoptosis and blocking the cell cycle at the G2/M phase. The expression of ILK in patients with SqCC was significantly higher compared with those with adenocarcinoma with sensitizing EGFR mutations. In addition, the cell cycle pathway ‘G2/M DNA damage and checkpoint regulation’ was identified to be significantly inhibited by ILK knockdown in IPA, KEGG and GO analysis. The results of the present study may improve the understanding of EGFR‑TKI resistance in lung SqCCs, thus promoting the development of potential targeted therapies for lung SqCCs.

View Figures

View References

1	Wahbah M, Boroumand N, Castro C, El-Zeky F and Eltorky M: Changing trends in the distribution of the histologic types of lung cancer: A review of 4439 cases. Ann Diagn Pathol. 11:89–96. 2007. View Article : Google Scholar : PubMed/NCBI
2	Camidge DR, Doebele RC and Kerr KM: Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 16:341–355. 2019. View Article : Google Scholar : PubMed/NCBI
3	Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, Jänne PA, Kuo FC, Oxnard GR and Sholl LM: Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer. 140:35–41. 2020. View Article : Google Scholar : PubMed/NCBI
4	National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Plymouth; PA: 2018
5	Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, et al: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019. View Article : Google Scholar : PubMed/NCBI
6	Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Märten A and Cufer T: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study. Future Oncol. 15:2905–2914. 2019. View Article : Google Scholar : PubMed/NCBI
7	Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
8	Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 387:1540–1550. 2016. View Article : Google Scholar : PubMed/NCBI
9	Solassol I, Pinguet F and Quantin X: FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: Safety, tolerability, plasma concentration monitoring, and management. Biomolecules. 9:6682019. View Article : Google Scholar
10	Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C and Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 21:3798–3807. 2003. View Article : Google Scholar : PubMed/NCBI
11	Cancer Genome Atlas Research Network, . Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
12	Wang Z, Shen Z, Li Z, Duan J, Fu S, Liu Z, Bai H, Zhang Z, Zhao J, Wang X and Wang J: Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs inlung squamous cell carcinoma patients with EGFR mutations. Proc Natl Acad Sci USA. 112:9990–9995. 2015. View Article : Google Scholar : PubMed/NCBI
13	Hata A, Katakami N, Yoshioka H, Kunimasa K, Fujita S, Kaji R, Notohara K, Imai Y, Tachikawa R, Tomii K, et al: How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? J Thorac Oncol. 8:89–95. 2013. View Article : Google Scholar : PubMed/NCBI
14	Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, et al: Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports. Cancer Sci. 102:1032–1037. 2011. View Article : Google Scholar : PubMed/NCBI
15	Filipits M: New developments in the treatment of squamous cell lung cancer. Curr Opin Oncol. 26:152–158. 2014. View Article : Google Scholar : PubMed/NCBI
16	Schwaederle M, Elkin SK, Tomson BN, Carter JL and Kurzrock R: Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. Cell Cycle. 14:2355–2361. 2015. View Article : Google Scholar : PubMed/NCBI
17	Goss GD and Spaans JN: Epidermal growth factor receptor inhibition in the management of squamous cell carcinoma of the lung. Oncologist. 21:205–213. 2016. View Article : Google Scholar : PubMed/NCBI
18	Memon AA, Zhang H, Gu Y, Luo Q, Shi J, Deng Z, Ma J and Ma W: EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma. Onco Targets Ther. 10:4607–4613. 2017. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Ray P, Raghunathan K, Ahsan A, Allam US, Shukla S, Basrur V, Veatch S, Lawrence TS, Nyati MK and Ray D: Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance. J Biol Chem. 295:12661–12673. 2020. View Article : Google Scholar : PubMed/NCBI
21	Lei T, Zhang L, Song Y, Wang B, Shen Y, Zhang N and Yang M: miR-1262 Transcriptionally modulated by an enhancer genetic variant improves efficiency of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced lung adenocarcinoma. DNA Cell Biol. 39:1111–1118. 2020. View Article : Google Scholar : PubMed/NCBI
22	Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, et al: A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 12:eaaz45892020. View Article : Google Scholar : PubMed/NCBI
23	Rong X, Liang Y, Han Q, Zhao Y, Jiang G, Zhang X, Lin X, Liu Y, Zhang Y, Han X, et al: Molecular mechanisms of tyrosine kinase inhibitor resistance induced by membranous/cytoplasmic/nuclear translocation of epidermal growth factor receptor. J Thorac Oncol. 14:1766–1783. 2019. View Article : Google Scholar : PubMed/NCBI
24	Pinheiro FD, Teixeira AF, de Brito BB, da Silva FAF, Santos MLC and de Melo FF: Immunotherapy-new perspective in lung cancer. World J Clin Oncol. 11:250–259. 2020. View Article : Google Scholar : PubMed/NCBI
25	Assi K, Bergstrom K, Vallance B, Owen D and Salh B: Requirement of epithelial integrin-linked kinase for facilitation of Citrobacter rodentium-induced colitis. BMC Gastroenterol. 13:1372013. View Article : Google Scholar : PubMed/NCBI
26	Chen D, Zhang Y, Zhang X, Li J, Han B, Liu S, Wang L, Ling Y, Mao S and Wang X: Overexpression of integrin-linked kinase correlates with malignant phenotype in non-small cell lung cancer and promotes lung cancer cell invasion and migration via regulating epithelial-mesenchymal transition (EMT)-related genes. Acta Histochem. 115:128–136. 2013. View Article : Google Scholar : PubMed/NCBI
27	Espinoza I and Miele L: Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett. 341:41–45. 2013. View Article : Google Scholar : PubMed/NCBI
28	Yu J, Shi R, Zhang D, Wang E and Qiu X: Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: Correlation with E-cadherin expression, tumor microvessel density and clinical outcome. Virchows Arch. 458:99–107. 2011. View Article : Google Scholar : PubMed/NCBI
29	Posch F, Setinek U, Flores RM, Bernhard D, Hannigan GE, Mueller MR and Watzka SB: Serum integrin-linked kinase (sILK) concentration and survival in non-small cell lung cancer: A pilot study. Clin Transl Oncol. 16:455–462. 2014. View Article : Google Scholar : PubMed/NCBI
30	Jia Z: Role of integrin-linked kinase in drug resistance of lung cancer. Onco Targets Ther. 8:1561–1565. 2015. View Article : Google Scholar : PubMed/NCBI
31	Augustin A, Lamerz J, Meistermann H, Golling S, Scheiblich S, Hermann JC, Duchateau-Nguyen G, Tzouros M, Avila DW, Langen H, et al: Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines. Mol Cancer Ther. 12:520–529. 2013. View Article : Google Scholar : PubMed/NCBI
32	Liu M, Xu S, Wang Y, Li Y, Li Y, Zhang H, Liu H and Chen J: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Oncotarget. 7:84951–84964. 2016. View Article : Google Scholar : PubMed/NCBI
33	Dermawan JK, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N and Stark GR: Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther. 13:2203–2214. 2014. View Article : Google Scholar : PubMed/NCBI
34	Kaylan KB, Gentile SD, Milling LE, Bhinge KN, Kosari F and Underhill GH: Mapping lung tumor cell drug responses as a function of matrix context and genotype using cell microarrays. Integr Biol (Camb). 8:1221–1231. 2016. View Article : Google Scholar : PubMed/NCBI
35	Wang J, Wang B, Chu H and Yao Y: Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther. 9:3711–3726. 2016. View Article : Google Scholar : PubMed/NCBI
36	Salmela AL and Kallio MJ: Mitosis as an anti-cancer drug target. Chromosoma. 122:431–449. 2013. View Article : Google Scholar : PubMed/NCBI